Jonathan Z Li1, Andrea Heisey, Hayat Ahmed, Hongying Wang, Lu Zheng, Mary Carrington, Terri Wrin, Robert T Schooley, Michael M Lederman, Daniel R Kuritzkes. 1. aBrigham and Women's Hospital, Harvard Med School bHarvard School of Public Health, Boston, Massachusetts cCancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research Institute, Frederick National Laboratory for Cancer Research, Frederick, Maryland dRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts eMonogram Biosciences fUniversity of California, San Diego, La Jolla, California gCase Western Reserve University, Cleveland, Ohio, USA.
Abstract
OBJECTIVES: The objective of this study is to evaluate the impact of therapeutic HIV vaccination on the HIV reservoir and assess the relationship of the viral reservoir with HIV-specific immune status and viral rebound kinetics. DESIGN: A retrospective analysis of ACTG A5197, a randomized, placebo-controlled trial of a therapeutic rAd5 HIV-1 gag vaccine. METHODS: Participants received vaccine/placebo at weeks 0, 4 and 26 prior to a 16-week analytic treatment interruption (ATI) at week 38. Cell-associated HIV-1 RNA and DNA (CA-RNA and CA-DNA) and HIV-1 residual viremia were quantified at weeks 0, 8 and 38. HIV-specific CD4(+)/CD8(+) activity was assessed by an intracellular cytokine staining assay. RESULTS: At study entry, CA-RNA and CA-DNA levels were correlated inversely with the numbers of HIV-specific CD4(+) interferon-γ producing cells (CA-RNA: r = -0.23, P = 0.03 and CA-DNA: r = -0.28, P < 0.01, N = 93). Therapeutic HIV vaccination induced HIV-specific CD4(+) activity, but did not significantly affect levels of CA-RNA or CA-DNA. Vaccine recipients with undetectable residual viremia at week 8 had higher frequencies of HIV-specific CD4(+) and CD8(+) interferon-γ producing cells (undetectable versus detectable residual viremia: 277 versus 161 CD4(+) cells/10(6) lymphocytes, P = 0.03 and 1326 versus 669 CD8(+) cells/10 lymphocytes, P = 0.04). Pre-ATI CA-RNA and CA-DNA were associated with post-ATI plasma HIV set point (CA-RNA: r = 0.51, P < 0.01 and CA-DNA: r = 0.47, P < 0.01). CONCLUSION:Vaccine-induced T-cell responses were associated with a modest transient effect on residual viremia, but more potent immune responses and/or combination treatment with latency-reversing agents are needed to reduce the HIV reservoir. HIV reservoir measures may act as biomarkers of post-ATI viral rebound kinetics. CLINICAL TRIALS REGISTRATION: NCT00080106.
RCT Entities:
OBJECTIVES: The objective of this study is to evaluate the impact of therapeutic HIV vaccination on the HIV reservoir and assess the relationship of the viral reservoir with HIV-specific immune status and viral rebound kinetics. DESIGN: A retrospective analysis of ACTG A5197, a randomized, placebo-controlled trial of a therapeutic rAd5 HIV-1gag vaccine. METHODS:Participants received vaccine/placebo at weeks 0, 4 and 26 prior to a 16-week analytic treatment interruption (ATI) at week 38. Cell-associated HIV-1 RNA and DNA (CA-RNA and CA-DNA) and HIV-1 residual viremia were quantified at weeks 0, 8 and 38. HIV-specific CD4(+)/CD8(+) activity was assessed by an intracellular cytokine staining assay. RESULTS: At study entry, CA-RNA and CA-DNA levels were correlated inversely with the numbers of HIV-specific CD4(+) interferon-γ producing cells (CA-RNA: r = -0.23, P = 0.03 and CA-DNA: r = -0.28, P < 0.01, N = 93). Therapeutic HIV vaccination induced HIV-specific CD4(+) activity, but did not significantly affect levels of CA-RNA or CA-DNA. Vaccine recipients with undetectable residual viremia at week 8 had higher frequencies of HIV-specific CD4(+) and CD8(+) interferon-γ producing cells (undetectable versus detectable residual viremia: 277 versus 161 CD4(+) cells/10(6) lymphocytes, P = 0.03 and 1326 versus 669 CD8(+) cells/10 lymphocytes, P = 0.04). Pre-ATI CA-RNA and CA-DNA were associated with post-ATI plasma HIV set point (CA-RNA: r = 0.51, P < 0.01 and CA-DNA: r = 0.47, P < 0.01). CONCLUSION: Vaccine-induced T-cell responses were associated with a modest transient effect on residual viremia, but more potent immune responses and/or combination treatment with latency-reversing agents are needed to reduce the HIV reservoir. HIV reservoir measures may act as biomarkers of post-ATI viral rebound kinetics. CLINICAL TRIALS REGISTRATION: NCT00080106.
Authors: Robert J McLinden; Robert M Paris; Victoria R Polonis; Nicole C Close; Zhaohui Su; Cecilia M Shikuma; David M Margolis; Jerome H Kim Journal: AIDS Date: 2012-01-02 Impact factor: 4.177
Authors: Joseph P Casazza; Kathryn A Bowman; Selorm Adzaku; Emily C Smith; Mary E Enama; Robert T Bailer; David A Price; Emma Gostick; Ingelise J Gordon; David R Ambrozak; Martha C Nason; Mario Roederer; Charla A Andrews; Frank M Maldarelli; Ann Wiegand; Mary F Kearney; Deborah Persaud; Carrie Ziemniak; Raphael Gottardo; Julie E Ledgerwood; Barney S Graham; Richard A Koup Journal: J Infect Dis Date: 2013-03-12 Impact factor: 5.226
Authors: Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin Journal: J Clin Microbiol Date: 2003-10 Impact factor: 5.948
Authors: Ellen Van Gulck; Lotte Bracke; Leo Heyndrickx; Sandra Coppens; Derek Atkinson; Céline Merlin; Alexander Pasternak; Eric Florence; Guido Vanham Journal: PLoS One Date: 2012-05-30 Impact factor: 3.240
Authors: Erin H Graf; Matthew J Pace; Bennett A Peterson; Lindsay J Lynch; Steve B Chukwulebe; Angela M Mexas; Farida Shaheen; Jeffrey N Martin; Steven G Deeks; Mark Connors; Stephen A Migueles; Una O'Doherty Journal: PLoS One Date: 2013-08-07 Impact factor: 3.240
Authors: Susanne Eriksson; Erin H Graf; Viktor Dahl; Matthew C Strain; Steven A Yukl; Elena S Lysenko; Ronald J Bosch; Jun Lai; Stanley Chioma; Fatemeh Emad; Mohamed Abdel-Mohsen; Rebecca Hoh; Frederick Hecht; Peter Hunt; Ma Somsouk; Joseph Wong; Rowena Johnston; Robert F Siliciano; Douglas D Richman; Una O'Doherty; Sarah Palmer; Steven G Deeks; Janet D Siliciano Journal: PLoS Pathog Date: 2013-02-14 Impact factor: 6.823
Authors: N M Archin; A L Liberty; A D Kashuba; S K Choudhary; J D Kuruc; A M Crooks; D C Parker; E M Anderson; M F Kearney; M C Strain; D D Richman; M G Hudgens; R J Bosch; J M Coffin; J J Eron; D J Hazuda; D M Margolis Journal: Nature Date: 2012-07-25 Impact factor: 49.962
Authors: Mary F Kearney; Ann Wiegand; Wei Shao; John M Coffin; John W Mellors; Michael Lederman; Rajesh T Gandhi; Brandon F Keele; Jonathan Z Li Journal: J Virol Date: 2015-11-18 Impact factor: 5.103
Authors: Maria M Bednar; Blake M Hauser; Shuntai Zhou; Jeffrey M Jacobson; Joseph J Eron; Ian Frank; Ronald Swanstrom Journal: J Infect Dis Date: 2016-04-30 Impact factor: 5.226
Authors: Jun Yong Choi; Antoine Chaillon; Jin Ok Oh; Jin Young Ahn; Hae Won Ann; In Young Jung; Mi-Young Ahn; Yong Duk Jeon; Nam Su Ku; Davey M Smith; June Myung Kim Journal: J Med Virol Date: 2015-09-21 Impact factor: 2.327
Authors: Jonathan Z Li; Behzad Etemad; Hayat Ahmed; Evgenia Aga; Ronald J Bosch; John W Mellors; Daniel R Kuritzkes; Michael M Lederman; Michael Para; Rajesh T Gandhi Journal: AIDS Date: 2016-01-28 Impact factor: 4.177
Authors: P Palma; C Foster; P Rojo; P Zangari; A Yates; N Cotugno; N Klein; K Luzuriaga; S Pahwa; E Nastouli; D M Gibb; W Borkowsky; S Bernardi; V Calvez; E Manno; Nadia Mora; A Compagnucci; B Wahren; Má Muñoz-Fernández; A De Rossi; J Ananworanich; D Pillay; C Giaquinto; P Rossi Journal: J Virus Erad Date: 2015-06-30